Patents Examined by Karen Cochrane Carlson
  • Patent number: 10150803
    Abstract: The present invention relates a method of preparing a Glucagon-like peptide 2 (GLP-2) analog by gene recombination. The present invention provides an expression vector, which includes: (a) a nucleic acid sequence encoding tag protein; (b) a nucleic acid sequence encoding Smt3 protein (SEQ ID NO: 1); and (c) a nucleic acid sequence encoding linker peptide (SEQ ID NO: 2) and GLP-2 analog. The fusion protein expressed by the expression vector can be cleaved by thrombin, wherein the cleaving position is at the linker peptide, and then the GLP-2 analog is produced.
    Type: Grant
    Filed: January 17, 2017
    Date of Patent: December 11, 2018
    Assignee: CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO. LTD
    Inventors: Shih-Lin Chen, Ting-Yu Hsiung
  • Patent number: 10150957
    Abstract: The present invention relates to protease variants and methods for obtaining protease variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Grant
    Filed: July 28, 2014
    Date of Patent: December 11, 2018
    Assignee: Novozymes A/S
    Inventors: Frank Winther Rasmussen, Rolf Thomas Lenhard, Miguel Duarte Guilherme Perreira Toscano, Esben Peter Friis, Signe Eskildsen Larsen, Jurgen Carsten Franz Knotzel, Mikael Bauer
  • Patent number: 10144941
    Abstract: A method of digesting a lignocellulosic material is disclosed. In one embodiment, the method comprises the step of exposing the material to an effective amount of Streptomyces sp. ActE secretome such that at least partial lignocellulosic digestion occurs.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: December 4, 2018
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Brian Grant Fox, Taichi Takasuka, Adam Joel Book, Cameron Robert Currie
  • Patent number: 10117905
    Abstract: The present invention relates to compositions comprising peptides that may be variants, derivatives and structural equivalents of cupredoxins that inhibit the development of premalignant lesions in mammalian cells, tissues and animals. Specifically, these compositions may comprise azurin from Pseudomonas aeruginosa, and/or the 50-77 residue region of azurin (p28). The present invention further relates to compositions that may comprise cupredoxin(s), and/or variants, derivatives or structural equivalents of cupredoxins, that retain the ability to inhibit the development of premalignant lesions in mammalian cells, tissues or animals. These compositions may be peptides or pharmaceutical compositions, among others. The compositions of the invention may be used to prevent the development of premalignant lesions in mammalian cells, tissues and animals, and thus prevent cancer.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: November 6, 2018
    Inventors: Tapas Das Gupta, Ananda Chakrabarty
  • Patent number: 10113159
    Abstract: The present invention relates to polypeptides for use in suppressing cancer and cancer disorders. The treatment employs use of a non-cytotoxic protease, which is targeted to the cancer cell, and, when so delivered, the protease is internalized and inhibits secretion from the cancer cell.
    Type: Grant
    Filed: June 4, 2014
    Date of Patent: October 30, 2018
    Assignee: Ipsen Bioinnovation Limited
    Inventors: Frederic Madec, Philip Lecane, Philip Marks, Keith Foster
  • Patent number: 10111926
    Abstract: The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: October 30, 2018
    Assignees: The Regents of the University of California, C3 Jian, LLC
    Inventors: Randal H. Eckert, Daniel K. Yarbrough, Wenyuan Shi, Maxwell H. Anderson, Fengxia Qi, Jian He, Ian H. McHardy
  • Patent number: 10105420
    Abstract: Methods and compositions are provided for treating human synovial sarcoma (SS). Also provided are screens to identify therapeutics for the treatment of synovial sarcoma. These methods, compositions, and screens are based on the discovery that promoting the assembly of wild type BAF (also called mSWI/SNF) complexes in SS cells by increasing levels of wild type SS18 and/or decreasing levels of SS18-SSX fusion protein leads to the cessation of proliferation of malignant cells in synovial sarcoma.
    Type: Grant
    Filed: July 20, 2016
    Date of Patent: October 23, 2018
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Cigall Kadoch, Gerald R. Crabtree
  • Patent number: 10100340
    Abstract: A method for culturing a protist of the Aurantiochytrium mangrovei genus. The genus is characterized genetically and by virtue of the lipid profile thereof. The method makes it possible to obtain a high biomass yield and a lipid, and more particularly docosahexaenoic acid (DHA), enrichment of the protists thus cultured. The development of a culture medium allows the production, at high cell density, of a DHA-rich protest of the Aurantiochytrium mangrovei genus. The medium is chemically defined at low sodium ion (Na+) and chloride ion (Cl?) content.
    Type: Grant
    Filed: April 3, 2015
    Date of Patent: October 16, 2018
    Assignee: FERMENTALG
    Inventors: Pierre Calleja, Julien Pagliardini, Olivier Cagnac, Francois Godart
  • Patent number: 10092009
    Abstract: The present invention is generally directed to fusion proteins containing a targeting sequence that targets the fusion protein to the exosporium of a Bacillus cereus family member. The invention also relates to recombinant Bacillus cereus family members expressing such fusion proteins, formulations containing the recombinant Bacillus cereus family members expressing the fusion proteins. Methods for stimulating plant growth and for protecting plants from pathogens by applying the recombinant Bacillus cereus family members or the formulations to plants or a plant growth medium are also described. The invention also relates to methods for immobilizing spores of a recombinant Bacillus cereus family member expressing a fusion protein on plant roots.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: October 9, 2018
    Assignee: Spogen Biotech Inc.
    Inventors: Brian Thompson, Katie Thompson
  • Patent number: 10093956
    Abstract: The subject invention pertains to methods and apparatus for the production and purification of cell products, such as immunoglobulins. One aspect of the invention is an integrated cell culture and purification apparatus for the growth and maintenance of cells and the harvest and purification of cell products, such as immunoglobulins. Thus, the apparatus integrates a cell culture function with a purification function. Other aspects of the invention pertain to an automated method for producing immunogenic compositions such as vaccines.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: October 9, 2018
    Assignee: BIOVEST INTERNATIONAL, INC.
    Inventors: Mark Hirschel, Robert J. Wojciechowski, Grant Adams, Darrell P. Page, Kimberly Arneson, Jeff Jorgensen, Scott Waniger
  • Patent number: 10093910
    Abstract: Engineered CRISPR-Cas9 nucleases with improved specificity and their use in genomic engineering, epigenomic engineering, genome targeting, and genome editing.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: October 9, 2018
    Assignee: The General Hospital Corporation
    Inventors: J. Keith Joung, Benjamin Kleinstiver, Vikram Pattanayak
  • Patent number: 10087470
    Abstract: A non-naturally occurring microbial organism includes a microbial organism having a reductive TCA or Wood-Ljungdahl pathway in which at least one exogenous nucleic acid encoding these pathway enzymes is expressed in a sufficient amount to enhance carbon flux through acetyl-CoA. A method for enhancing carbon flux through acetyl-CoA includes culturing theses non-naturally occurring microbial organisms under conditions and for a sufficient period of time to produce a product having acetyl-CoA as a building block. Another non-naturally occurring microbial organism includes at least one exogenous nucleic acid encoding an enzyme expressed in a sufficient amount to enhance the availability of reducing equivalents in the presence of carbon monoxide or hydrogen, thereby increasing the yield of redox-limited products via carbohydrate-based carbon feedstock.
    Type: Grant
    Filed: July 22, 2015
    Date of Patent: October 2, 2018
    Assignee: Genomatica, Inc.
    Inventors: Anthony P. Burgard, Robin E. Osterhout, Jun Sun, Priti Pharkya
  • Patent number: 10086050
    Abstract: The present invention relates to Surfactant Protein D (SP-D) or nucleic acids encoding SP-D or variants thereof such as surfactant protein A or mannan binding lectin for use in the treatment and/or prevention of a parasitic infection. Methods for determining the presence of a parasitic infection by determining levels of SP-D in a sample are also disclosed. Also disclosed are helminths for treating allergy, inflammation or infection.
    Type: Grant
    Filed: February 19, 2015
    Date of Patent: October 2, 2018
    Assignees: University of Southampton, University of Cape Town
    Inventors: Howard William Clark, William Horsnell
  • Patent number: 10076574
    Abstract: Methods for treating a subject in need thereof are provided which include administering a pharmaceutical composition comprising a protein transduction reagent-modified reprogramming protein to the subject, wherein the protein transduction reagent is non-covalently bound to the reprogramming protein and wherein the protein transduction reagent comprises a cation reagent and a lipid. According to aspects, such methods provide delivery of protein-transduction reagent-modified reprogramming proteins to cancer cells, such as tumor cells, as well as diseased cells of diseased tissues and provide in vivo conversion of diseased cells into normal cells via protein-induced in situ cell reprogramming without administration of nucleic acids to the subject.
    Type: Grant
    Filed: October 27, 2014
    Date of Patent: September 18, 2018
    Assignee: Wayne State University
    Inventors: Jianjun Wang, Qianqian Li, Michael Chopp, Feng Jiang, Guojun Wu
  • Patent number: 10077453
    Abstract: Some aspects of this disclosure provide compositions, methods, systems, and kits for controlling the activity of RNA-programmable endonucleases, such as Cas9, or for controlling the activity of proteins comprising a Cas9 variant fused to a functional effector domain, such as a nuclease, nickase, recombinase, deaminase, transcriptional activator, transcriptional repressor, or epigenetic modifying domain. For example, the inventive proteins provided comprise a ligand-dependent intein, the presence of which inhibits one or more activities of the protein (e.g., gRNA binding, enzymatic activity, target DNA binding). The binding of a ligand to the intein results in self-excision of the intein, restoring the activity of the protein.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: September 18, 2018
    Assignee: President and Fellows of Harvard College
    Inventors: David R. Liu, Kevin Davis
  • Patent number: 10072236
    Abstract: The present invention relates to detergent compositions comprising protease variants and methods for obtaining such detergent compositions. The present invention also relates to the use of such detergent compositions, especially in laundry or in hard surface cleaning applications.
    Type: Grant
    Filed: July 28, 2014
    Date of Patent: September 11, 2018
    Assignee: Henkel AG & Co. KGaA
    Inventors: Timothy O'Connell, Susanne Tondera, Hendrik Hellmuth, Thomas Weber, Frank Winther Rasmussen, Rolf Thomas Lenhard, Miguel Duarte Guilherme Pereira Toscano, Esben Friis, Signe Eskildsen Larsen, Juergen Carsten Franz Knoetzel, Mikael Bauer
  • Patent number: 10072276
    Abstract: Provided is a genetically engineered yeast cell having increased NADPH production, a method of increasing a NADPH level in a yeast cell, a method of preparing the genetically engineered yeast cell, and a method of producing lactate using the genetically engineered yeast cell.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: September 11, 2018
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Yukyung Jung, Kwangmyung Cho, Jinha Kim, Soonchun Chung
  • Patent number: 10066025
    Abstract: The invention described herein relates to the discovery that renalase, and fragments thereof, are useful for the treatment or prevention of cardiac and renal diseases or disorders. Thus, the invention relates to compositions comprising renalase, or fragments thereof, and methods for treating and preventing cardiac and renal disease or disorders.
    Type: Grant
    Filed: July 16, 2013
    Date of Patent: September 4, 2018
    Assignee: YALE UNIVERSITY
    Inventor: Gary Desir
  • Patent number: 10059754
    Abstract: The present invention describes methods and processes for the production of proteins, particularly glycoproteins, by animal cell or mammalian cell culture, preferably, but not limited to, fed-batch cell cultures. In one aspect, the methods comprise the addition of glucocorticoid compound during the culturing period. The addition of glucocorticoid compound sustain a high viability of the cultured cells, and can yield an increased end titer of protein product, and a high quality of protein product, as determined, e.g., by sialic acid content of the produced protein.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: August 28, 2018
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Ying Jing, Zhengjian Li, Yueming Qian
  • Patent number: 10052367
    Abstract: The present invention includes compositions and methods for treating disease and disorders associated with pathological calcification or pathological ossification by modulating the level or activity of NPP1 or a mutant thereof, or a mutant NPP4 modified to exhibit ATP hydrolase activity similar to the hydrolase activity of NPP1.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: August 21, 2018
    Assignee: Yale University
    Inventors: Demetrios Braddock, Ronald Albright